1 Nonalcoholic Fatty Liver Disease in South Asia.

2 Associations of mental distress with residency in conflict zones, ethnic minority status, and potentially modifiable social factors following conflict in Sri Lanka: a nationwide cross-sectional study.

3 Whole Grain Consumption and Its Effects on Hepatic Steatosis and Liver Enzymes in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial.

4 Addition of fish oil to atherogenic high fat diet inhibited atherogenesis while olive oil did not, in LDL receptor KO mice.

5 Active Helicobacter pylori Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients

6 Active Helicobacter pylori Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients

7 Psoralea corylifolia L. Seed Extract Attenuates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced Obese Mice

8 bariatric surgery and nonalcoholic fatty liver disease: current and potential future treatments

9 the state of pancreatobiliary system and intestinal microflora in children with nonalcoholic fatty liver disease

10 efficacy of acetylshikonin in preventing obesity and hepatic steatosis in db/db mice

11 essential phospholipids in the treatment of nonalcoholic fatty liver disease

12 practical approaches to the nutritional management of nonalcoholic fatty liver disease

13 safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic fatty liver disease

14 influence of nutrient correction on adiponectin circulating level and cardiovascular risk factors in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease

15 development of a non-invasive model to improve the accuracy of determining liver fibrosis stage in nonalcoholic fatty liver disease

16 Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial.

17 Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease.

18 A Mediterranean Diet Rich in Extra-Virgin Olive Oil Is Associated with a Reduced Prevalence of Nonalcoholic Fatty Liver Disease in Older Individuals at High Cardiovascular Risk.

19 Evaluation of diffusion kurtosis imaging in stratification of nonalcoholic fatty liver disease and early diagnosis of nonalcoholic steatohepatitis in a rabbit model.

20 Association Between Nonalcoholic Fatty Liver Disease and Severe Male Reproductive Organ Impairment (Germinal Epithelial Loss): Study on a Mouse Model and on Human Patients

21 [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].

22 Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease

23 Inhibition of lncRNA HULC improves hepatic fibrosis and hepatocyte apoptosis by inhibiting the MAPK signaling pathway in rats with nonalcoholic fatty liver disease

24 Erratum: Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease (Cell Metabolism (2017) 25(5) (1054–1062.e5), (S1550413117302061), (10.1016/j.cmet.2017.04.001))

25 Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease

26 Validation Study of Elastographies in Patients With Nonalcoholic Fatty Liver Disease for Detecting Liver Fibrosis

27 Raw Bowl Tea (Tuocha) Polyphenol Prevention of Nonalcoholic Fatty Liver Disease by Regulating Intestinal Function in Mice.

28 Hepatic Mitochondrial Defects in a Nonalcoholic Fatty Liver Disease Mouse Model Are Associated with Increased Degradation of Oxidative Phosphorylation Subunits.

29 Leptin/adiponectin ratio correlates with hepatic steatosis but not arterial stiffness in nonalcoholic fatty liver disease in Japanese population

30 Fat and sugar—a dangerous duet. A comparative review on metabolic remodeling in rodent models of nonalcoholic fatty liver disease

31 Asporin levels are low in patients with nonalcoholic fatty liver disease and increase after vitamin E treatment.

32 Copper modulates sex-specific fructose hepatoxicity in nonalcoholic fatty liver disease (NALFD) Wistar rat models.

33 Effects of green tea or green tea catechin on liver enzymes in healthy individuals and people with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized clinical trials

34 The effect of green tea extract supplementation on liver enzymes in patients with nonalcoholic fatty liver disease

35 THE THERAPEUTIC IMPACT OF PROBIOTICS ON NONALCOHOLIC FATTY LIVER DISEASE IN PEDIATRICS: A SYSTEMATIC REVIEW

36 obese children with metabolic syndrome have 3 times higher risk to have nonalcoholic fatty liver disease compared with those without metabolic syndrome

37 investigating the deregulation of metabolic tasks via minimum network enrichment analysis (minea) as applied to nonalcoholic fatty liver disease using mouse and human omics data.

38 mechanisms and implications of age-related changes in the liver: nonalcoholic fatty liver disease in the elderly

39 misregulation of ppar functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity

40 resveratrol inhibits nonalcoholic fatty liver disease in rats

41 the potential role of iron and copper in pediatric obesity and nonalcoholic fatty liver disease

42 the relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome

43 the effects of melatonin in patients with nonalcoholic fatty liver disease: a randomized controlled trial

44 diet-induced metabolic hamster model of nonalcoholic fatty liver disease

45 a review of western and traditional chinese medical approaches to managing nonalcoholic fatty liver disease

46 nonalcoholic fatty liver disease: a clinical approach and review

47 fbxw7 suppresses hmgb1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease

48 correlation of liver fat content with serum vitamin a level and insulin resistance in patients with nonalcoholic fatty liver disease

49 the dual role of nrf2 in nonalcoholic fatty liver disease: regulation of antioxidant defenses and hepatic lipid metabolism

50 rimonabant improves oxidative/nitrosative stress in mice with nonalcoholic fatty liver disease

51 nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes

52 a noninvasive score model for prediction of nash in patients with chronic hepatitis b and nonalcoholic fatty liver disease

53 developmental programming of nonalcoholic fatty liver disease: the effect of early life nutrition on susceptibility and disease severity in later life

54 the gut microbiota, intestinal permeability, bacterial translocation, and nonalcoholic fatty liver disease: what comes first?

55 effect of alkaloids from nelumbinis plumula against insulin resistance of high-fat diet-induced nonalcoholic fatty liver disease in mice

56 peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic fatty liver disease: any role in disease susceptibility?

57 pathology of nonalcoholic fatty liver disease (nafld) associated with obesity: pathogenetic mechanisms

58 chronic kidney disease and nonalcoholic fatty liver disease—is there a link?

59 obesity and nonalcoholic fatty liver disease: metabolic risks and their correction

60 establishment and comparison of juvenile female mouse models of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

61 Endotoxin Producers Overgrowing in Human Gut Microbiota as the Causative Agents for Nonalcoholic Fatty Liver Disease

Keyword Connections

Journals

Research Groups

Bibliographies